Ruth Knight1, Mizanur Khondoker2, Nicholas Magill1, Robert Stewart3,4, Sabine Landau1. 1. Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. 2. Norwich Medical School, University of East Anglia, Norwich, United Kingdom. 3. Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. 4. South London and Maudsley NHS Foundation Trust, London, United Kingdom.
Abstract
BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. SUMMARY: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2.11 MMSE points at 6 months) as for patients with Alzheimer disease/vascular dementia (0.91 MMSE points at 6 months). Key Messages: AChEIs demonstrate a modest effect versus control on MMSE scores which is moderated by dementia subtype. For memantine the effect is smaller.
BACKGROUND:Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. SUMMARY: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2.11 MMSE points at 6 months) as for patients with Alzheimer disease/vascular dementia (0.91 MMSE points at 6 months). Key Messages: AChEIs demonstrate a modest effect versus control on MMSE scores which is moderated by dementia subtype. For memantine the effect is smaller.
Authors: Jonathan Vogelgsang; Bernhard Kis; Katrin Radenbach; Claus Wolff-Menzler; Kiriaki Mavridou; Charles Timäus; Stephan Gyßer; Jens Wiltfang; Philipp Hessmann Journal: Aging Clin Exp Res Date: 2019-07-08 Impact factor: 3.636
Authors: Sérgio M de Almeida; Clea E Ribeiro; Indianara Rotta; Scott Letendre; Michael Potter; Bin Tang; Meiri Batistela; Florin Vaida; Ronald J Ellis Journal: J Neurovirol Date: 2019-07-07 Impact factor: 2.643
Authors: Terence J Quinn; Edo Richard; Yvonne Teuschl; Thomas Gattringer; Melanie Hafdi; John T O'Brien; Niamh Merriman; Celine Gillebert; Hanne Huyglier; Ana Verdelho; Reinhold Schmidt; Emma Ghaziani; Hysse Forchammer; Sarah T Pendlebury; Rose Bruffaerts; Milija Mijajlovic; Bogna A Drozdowska; Emily Ball; Hugh S Markus Journal: Eur Stroke J Date: 2021-10-08
Authors: Mackenzie E Fowler; Nicole C Wright; Kristen Triebel; Gabrielle B Rocque; Marguerite R Irvin; Richard E Kennedy Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Prajakta P Masurkar; Satabdi Chatterjee; Jeffrey T Sherer; Hua Chen; Michael L Johnson; Rajender R Aparasu Journal: Drugs Aging Date: 2022-06-06 Impact factor: 4.271